Abstract
Background: In patients with uncontrolled asthma despite ICS/LABA, effects of adding LAMA and increasing ICS differ based on treatment outcome and may vary with age.
Aim: Analyse effects of adding umeclidinium (UMEC) and increasing fluticasone furoate (FF) on FEV1 and exacerbations by age.
Methods: CAPTAIN: Phase IIIA, randomised, double-blind, 24–52-week, parallel-group study in adults with asthma, pre-bronchodilator FEV1 ≥30% and <85% predicted, Asthma Control Questionnaire-6 score ≥1.5.
Treatment: once-daily FF/vilanterol (VI) (100/25, 200/25μg) or FF/UMEC/VI (100/31.25/25, 100/62.5/25, 200/31.25/25, 200/62.5/25μg) (Ellipta inhaler).
Outcomes: change from baseline in trough FEV1 at Wk 24 and annualised rate of moderate/severe exacerbations for <65- and ≥65-year subgroups (no upper age limit for study entry) for UMEC 62.5μg only.
Results: Adding UMEC was associated with a trend towards a greater reduction in exacerbations in the older subgroup vs patients <65 years, whereas increasing FF appeared to have a greater effect in patients <65 years (Figure). Effects of adding UMEC or increasing FF on trough FEV1 were less consistent with age (Figure).
Conclusions: Effects of adding UMEC or increasing FF dose on exacerbation rate may vary with age.
Method: GSK (205715/NCT02924688).
Footnotes
Cite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 2631.
This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2020